Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 1.00 |
| ▸ | NPC1 | O15118 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 3/20 | 1.00 |
| ▸ | RELA | Q04206 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.88 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.88 |
| ▸ | TP53 | P04637 | 6/20 | 0.88 |
| ▸ | MAPT | P10636 | 6/20 | 0.88 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.88 |
| ▸ | HPGD | P15428 | 5/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prunetin SCHEMBL29612430 | 0.95 | ALDH2 (1.00) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| Prunetin SCHEMBL73420 | 0.95 | ALDH2 (1.00) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| Biochanin SCHEMBL61258 | 0.93 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| Biochanin SCHEMBL29410271 | 0.93 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| 5-Hydroxy-7-Methoxyisoflavone SCHEMBL6142401 | 0.91 | RAB9A (0.83) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL26145337 | 0.90 | RAB9A (0.82) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL14070593 | 0.90 | NPC1 (0.82) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2313317 | 0.90 | NPC1 (0.81) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL12892701 | 0.90 | RAB9A (0.81) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL7045859 | 0.89 | RAB9A (0.80) | RAB9ANPC1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113185486-B | Antitumor agent 3-aryl-4H-chromen-4-one for the treatment of cancer | 肯塔基大学研究基金会 | 2024-05-10 | — | — | CN | disclosed |
| CN-114287612-B | Ginseng fungus fruiting body alcohol extract with function of enhancing physical exercise endurance and preparation method thereof | 安徽大学 | 2024-01-09 | — | — | CN | disclosed |
| US-20230149344-A1 | BIOCHANIN A DERIVATIVES FOR TREATMENT OF BEST1-RELATED RETINOPATHIES | UNIVERSITÄT REGENSBURG (AT) | 2023-05-18 | — | — | US | disclosed |
| US-20230149344-A1 | BIOCHANIN A DERIVATIVES FOR TREATMENT OF BEST1-RELATED RETINOPATHIES | UNIVERSITÄT REGENSBURG (AT) | 2023-05-18 | — | — | US | disclosed |
| CN-114287612-A | An alcoholic extract of fruit body of white ginseng fungus for improving exercise tolerance of organism, and its preparation method | 安徽大学 | 2022-04-08 | — | — | CN | disclosed |
| US-20210299131-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NATIONAL INSTITUTES OF HEALTH | 2021-09-30 | — | — | US | disclosed |
| CN-113185486-A | Antitumor 3-aryl-4H-chromen-4-ones for the treatment of cancer | 肯塔基大学研究基金会 | 2021-07-30 | — | — | CN | disclosed |
| CN-107667100-B | Antitumor 3-aryl-4H-chromen-4-ones for the treatment of cancer | 肯塔基大学研究基金会 | 2021-06-08 | — | — | CN | disclosed |
| US-10953017-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200171040-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RES INST (US) | 2020-06-04 | — | — | US | disclosed |
| WO-2010039679-A1 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2010-04-08 | — | — | WO | disclosed |
| US-20090124569-A1 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | NORTHWESTERN UNIVERSITY (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124569-A1 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | NORTHWESTERN UNIVERSITY (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2007115181-A9 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEM CO (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2003057210-A1 | COMPOSITIONS AND METHODS FOR INCREASING CELL PROLIFERATION COMPRISING A FLAVONOID | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20030125264-A1 | Methods For Treating Wounds | KIMBERLY-CLARK WORLDWIDE, INC. | 2003-07-03 | — | — | US | disclosed |
| WO-2002089757-A3 | USE OF ISOFLAVONES IN COSMETIC OR DERMATOLOGICAL PREPARATIONS | BEIERSDORF AG (DE) | 2003-03-13 | — | — | WO | disclosed |
| WO-2002089757-A2 | USE OF ISOFLAVONES IN COSMETIC OR DERMATOLOGICAL PREPARATIONS | BEIERSDORF AG (DE) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | RAB9A 3126/4885NPC1 362/4885SMN1; SMN2 3973/4885 |
| US-20200171040-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | RAB9A 2402/4885NPC1 467/4885SMN1; SMN2 29/4885 |
| US-20230149344-A1 | BIOCHANIN A DERIVATIVES FOR TREATMENT OF BEST1-RELATED RETINOPATHIES | SORBS1, SLC5A6, SLC20A1 | RAB9A 1919/4885NPC1 1509/4885SMN1; SMN2 252/4885 |
| US-20030125264-A1 | Methods For Treating Wounds | FGF2, MMP1, FIBP | RAB9A 3143/4885NPC1 3898/4885SMN1; SMN2 2793/4885 |
| US-20210299131-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | RAB9A 2402/4885NPC1 467/4885SMN1; SMN2 29/4885 |
| US-20090124569-A1 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | MAPK4, MAP4K4, MAP3K4 | RAB9A 2041/4885NPC1 2582/4885SMN1; SMN2 4692/4885 |
| US-10953017-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | NFKBIA, NFRKB, TFEB | RAB9A 2402/4885NPC1 467/4885SMN1; SMN2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.